Richard’s Big Walk 2024
Richard is Head of Security at University of Sheffield. He’s been inspired to take on the Big Walk because of a family member living with motor neurone disease. Richard has set himself the challenge of taking part in three different events to raise awareness and funds for MND research.
I am signed up for the Lakeland 3Day, the Black Mountain marathon and our very own Big Walk.
All my fundraising will go towards vital research to make a difference to people with MND. There is currently no cure for MND. Let's help our researchers develop treatments for people living with the condition now and pioneering breakthroughs to help future generations.
The Big Walk brings the university community closer together and by all playing our part to lend a helping hand we can support those in need."
Richard Yates
Richard is a Big Walk pro having taken part in the event multiple times before. He'll be taking on the 30 mile trek past Grindleford and Baslow then back to the city.
Support Richard's fundraising here
Sheffield researchers are working tirelessly to find a cure for this debilitating condition. Their ongoing research hopes to discover more effective treatments to improve the lives of patients living with the disease.
With your support, a much needed breakthrough in MND will come sooner, improving the lives of patients long into the future.
Will you support Sheffield researchers with a gift today?
About the appeal
MND affects around 5,000 people in the UK every year. It kills six people in the UK every day, with a third of those diagnosed losing their lives within just a year. Tragically, people die from this devastating disease because there are currently no treatments that can stop it. But there's hope.
Your gift in support of motor neurone disease research will make a difference now. It will support our researchers at SITraN to develop treatments and advances that positively impact the lives of patients and their families.
SITraN has demonstrated that having clinicians and researchers working alongside each other, taking what they learn in the labs straight to patients, really works. But in part due to its great success, the facility is facing chronic pressures for space and is operating beyond capacity, delaying advancements.
Now, a world-class sister facility will be built alongside SITraN that will double capacity, grow research and drug discovery programmes, and build on promising areas such as cell and gene therapy.
We know that SITraN’s next chapter will be written in part thanks to our incredible supporter community.
Will you help to write the next chapter for SITraN?